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A 42-year-old businessman of South Asian
descent presents with a prolonged history of
fatigue and bothersome joint pain in his
hands and wrists. The patient takes metformin
for type 2 diabetes and ramipril for hypertension. He consumes 3 martinis per night and
does not smoke. A physical examination shows
no active joints, and his abdomen is normal
with no evidence of chronic liver disease. Previous laboratory investigations showed elevated ferritin (660 [normal < 300] µg/L) and
hemoglobin (178 [normal 115–165] g/L), and
normal liver enzyme levels.

What is the most likely diagnosis?
Alcoholic and nonalcoholic fatty liver disease
are the most likely causes for the patient’s elevated ferritin, but hereditary hemochromatosis is
also possible. Hereditary hemochromatosis is a
genetic condition in which elevated iron stores
lead to iron deposition in the liver, heart, pancreas, skin, joints, pituitary gland and testis,
resulting in cirrhosis of the liver, heart failure,
diabetes, skin bronzing, arthritis, endocrine
abnormalities and cancer.1 However, the classic
“bronze diabetes” presentation is uncommon.1
What other diagnoses should be
considered?
Acute and chronic inflammation resulting from
infection, malignant growths, renal failure, liver
disease, metabolic syndrome and autoimmune
Box 1: Summary of recommendations from current clinical
guidelines3,4
•

Genetic testing should not be used to screen for hemochromatosis.

•

Patients with elevated transferrin saturation (> 0.45%) and ferritin
(> 300 μg/L) should undergo testing for the C282Y and H63D alleles of
the HFE gene.

•

Phlebotomy should be performed in patients with elevated transferrin
saturation and ferritin who have a positive result on genetic testing.

•

Patients who show evidence of iron overload, but who do not have a
positive result on genetic testing, should still be considered for
phlebotomy or liver biopsy if no other cause is apparent.

•

Elevated ferritin is very sensitive, but not specific, for iron-related liver
damage.
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conditions may lead to elevated ferritin.2 Environmental exposures including diet, alcohol and
medications, particularly iron administered
orally or intravenously, can also elevate ferritin
and increase the risk of pathological iron accumulation. Elevated ferritin in the context of elevated transferrin saturation suggests iron
accumulation.2
What investigations should be done?
A detailed history should be taken and a physical
examination should be performed. In addition,
iron stores should be assessed by measuring
transferrin saturation, and renal function should
be assessed by measuring serum creatinine.
Chronic hepatitis infection and inflammation can
be ruled out by serology and by determining the
erythrocyte sedimentation rate, respectively. The
patient should undergo investigations to assess
for metabolic syndrome, including glycated
hemoglobin, fasting glucose and a lipid profile.
Finally, liver ultrasonography should be done to
determine whether nonalcoholic fatty liver disease and cirrhosis are present.2
Should the patient undergo genetic
testing for hemochromatosis?
Genetic testing should not be used to screen for
hemochromatosis, but current guidelines3,4 suggest testing in patients with elevated transferrin
saturation (> 0.45%) and ferritin (> 300 µg/L)
(Box 1). Testing typically involves genotyping
two polymorphisms, C282Y and H63D, in the
hemochromatosis gene (HFE). A positive result
is defined as two copies (homozygosity) of the
C282Y allele, or a C282Y allele on one chromosome and an H63D allele on the other chromosome (compound heterozygosity).5 Less than
0.5% of people with European ancestry are
homozygous for C282Y, with even lower prevalences in other ethnicities.5 Although C282Y
homozygosity is found in about 80% of patients
with clinical hemochromatosis, iron overload
will not develop in 60%–80% of patients with a
positive test result.3 Other genetic causes of
hemochromatosis have been described, and iron
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overload may still develop in patients with a
negative result on standard HFE testing, particularly if the patient is not of European descent.3
What is this patient’s prognosis?
In the presence or absence of a positive result on
HFE testing, patients with biochemical evidence
of iron overload are at risk of cirrhosis of the
liver, cardiomyopathies, arthropathies and endocrinopathies resulting from the accumulation of
nontransferrin-bound iron. Hemochromatosisrelated cirrhosis typically occurs in patients with
ferritin levels higher than 1000 μg/L.3,4 Less than
10% of patients with HFE hemochromatosis
show end-organ manifestations.4
Are further investigations required if
hemochromatosis is diagnosed?
In cases of hemochromatosis with a ferritin level
higher than 1000 μg/L, a biopsy of the liver
should be considered.3 Initial noninvasive investigation with transient elastography can identify
advanced fibrosis and cirrhosis, although access
to such imaging may be limited in smaller centres.3 In patients with hemochromatosis-induced
cirrhosis of the liver, ultrasound surveillance for
hepatocellular carcinoma should be performed
every 6 to 12 months.4 Because cardiac involvement is unusual, electrocardiography and echocardiography are reserved for patients with clinical indications. 3 Radiological evaluation of
affected joints is appropriate.3
Does this patient require phlebotomy?
Phlebotomy is a safe procedure that is both therapeutic and diagnostic for hemochromatosis. It
should be performed in patients with elevated
ferritin and transferrin saturation.3 A patient’s
response to phlebotomy is diagnostic; patients
with pathological iron overload will require multiple phlebotomies, whereas patients with other
causes of elevated ferritin will show a rapid
decrease in ferritin.3 The recommended schedule
involves biweekly phlebotomy (500 mL), with
measurement of hemoglobin and ferritin at each
visit, continuing until the patient’s ferritin level
is less than 50 μg/L.3
Case resolution
Investigations for secondary causes of elevated
ferritin (i.e., creatinine, erythrocyte sedimentation rate, hepatitis serology and ultrasonography
of the liver) had normal results. Fasting glucose

and glycated hemoglobin results suggested adequate glucose control while taking metformin.
Mildy elevated triglycerides and reduced highdensity lipoprotein cholesterol were present;
however, a waist circumference of 88 cm
excluded a diagnosis of metabolic syndrome. A
transferrin saturation of 60% suggested hemochromatosis, but genetic testing showed no copies of the C282Y allele and a single copy of the
H63D allele. Despite these results, the patient
was counselled that his clinical presentation was
consistent with iron overload and arrangements
were made for therapeutic phlebotomy, which
would assist in confirming a diagnosis of hemochromatosis. In addition, the patient was counselled to stop consuming alcohol.
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Decisions is a series that focuses on practical
evidence-based approaches to common presentations in primary care. The articles address key
decisions that a clinician may encounter during initial assessment. The information presented can
usually be covered in a typical primary care appointment. Articles should be no longer than 650 words,
may include one box, figure or table and should
begin with a very brief description (75 words or
less) of the clinical situation. The decisions addressed should be presented in the form of
questions. A box providing helpful resources for the
patient or physician is encouraged.
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